Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of roflumilast plus alogliptin on
glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.